Laid-off pharma workers find equal or better jobs; Drugmakers helping Myanmar, China relief; and much more

> Many laid-off pharma workers are finding new jobs that are comparable to--even at higher levels then--those they left behind, a new survey shows; 84 percent did so without relocating. Report

> Big Pharma is giving millions of dollars in cash, medicines and vaccines to relief efforts in Myanmar and China, with GlaxoSmithKline and Pfizer the biggest donors so far at $1.5 million each. Report

> Scotland's biggest local health board is limiting Avandia prescriptions to those issued by diabetes specialists; GPs can no longer initiate treatment with the controversy-plagued GlaxoSmithKline drug. Report

> Medtronic reported flat earnings of $812 million on $3.86 billion in revenues for the fiscal fourth quarter, falling shy of analyst estimates. Report

> Dr Reddy's Laboratories reported a disappointing 68.3 percent drop in quarterly profits to $24 million. Report

> India's Dabur Oncology got U.S. FDA approval for the prostate cancer treatment Mitoxantrone Hydrochloride. Report

> Biotech entrepreneur John Oyler--who helped found Genta and Galanea--sat down with Chemistry World to discuss his three-year-old CRO, BioDuro. He and an old friend founded the CRO with their own money, choosing to base the contract research organization in Beijing rather than Shanghai, where the big multinational drug companies have flocked. CRO report

> LA-based Kythera Biopharmaceuticals is looking for a key assist in Japan from a new investor. JAFCO has led a $40 million Series C for the biotech developer of "aesthetic" therapies. Kythera report

> France's Ipsen gained $25 million from Medicis Pharmaceutical on the news that the FDA has accepted the BLA filing for Reloxin, a next-gen competitor to Allergan's Botox. Ipsen report

> A pair of analysts has taken a cautious attitude toward Aldagen's plans for an $80 million IPO. The stem-cell company has no products on the market, makes no profit and is attempting to pioneer an FDA approval in an emerging field. Report

And Finally... The flu drug amantadine had a starring role on the Fox drama "House" last night, then popped up as the top Google search this morning. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.